NuvoAir Medical Company Profile

Background

NuvoAir Medical is a digital health company specializing in the management of chronic respiratory and cardiopulmonary conditions. Founded in 2016, the company operates with a mission to deliver proactive, continuous virtual-first specialty care, ensuring that patients with complex heart and lung conditions receive timely and effective treatment. With headquarters in Boston, Massachusetts, and Stockholm, Sweden, NuvoAir serves patients across two continents, collaborating with health plans, risk-bearing entities, and innovative specialists to redefine cardiopulmonary care.

Key Strategic Focus

NuvoAir's strategic focus centers on providing value-based, patient-centric care through a virtual-first model. The company specializes in managing conditions such as Chronic Obstructive Pulmonary Disease (COPD), asthma, cystic fibrosis, heart failure, and sleep disorders. By integrating personalized care plans with advanced remote monitoring technologies, NuvoAir aims to reduce hospitalizations, improve patient outcomes, and lower overall healthcare costs.

Financials and Funding

As of 2023, NuvoAir reported a revenue of $29.7 million. The company has secured a total of $28.2 million in funding, including a $25 million Series A round in January 2022 led by AlbionVC and Hikma Ventures. These funds are intended to expand NuvoAir's virtual care services, enhance technological capabilities, and support partnerships with healthcare providers and payers.

Pipeline Development

NuvoAir is actively involved in clinical research to validate its virtual care model. In September 2023, the company launched a study in collaboration with Security Health Plan of Wisconsin to assess the impact of its virtual care services on reducing exacerbations, emergency room visits, hospitalizations, readmissions, and overall costs for COPD patients. This 12-month study aims to enroll up to 1,500 participants, highlighting NuvoAir's commitment to evidence-based care.

Technological Platform and Innovation

NuvoAir's technological platform is distinguished by several proprietary technologies and methodologies:

Air Next Spirometer: An FDA-cleared, ultra-portable spirometer that connects to smartphones, enabling patients to perform lung function tests at home.

Remote Monitoring Devices: The company provides patients with easy-to-use devices, including pulse oximeters, activity trackers, and blood pressure cuffs, facilitating continuous health monitoring.

AI-Driven Patient Management: NuvoAir employs artificial intelligence to analyze patient data, detect early signs of exacerbations, and tailor personalized care plans, enhancing proactive care delivery.

Leadership Team

Lorenzo Consoli: Founder and CEO, established NuvoAir in 2016 to transform cardiopulmonary care globally.

Dr. Eric Harker: Chief Medical Officer, a practicing internal medicine specialist with over 20 years of experience.

Chris Skowronek: Chief Growth Officer, with over 20 years of experience shaping sales strategies across the healthcare ecosystem.

Michael Zagami: Chief Product Officer, delivering innovative technology and services for health plans for over 15 years.

Manan Mehra: Chief Technology Officer, building scalable and innovative products with over 20 years of experience.

Samantha Yancich: Senior Director of People Operations, shaping and scaling a culture of innovation, accountability, and patient-focus.

Furat Shawki: General Manager of Clinical Trials, leading product development, sales, and operations for clinical trials.

Simon Lucas: General Manager of the UK Market, managing clinical services in the UK, including strategy, operations, sales, and growth.

Carisa Raucci: Vice President of Clinical Operations, with over two decades of healthcare industry and operational experience.

Leadership Changes

As of March 2025, there have been no recent significant changes or appointments within NuvoAir's leadership team.

Competitor Profile

Market Insights and Dynamics

The market for managing chronic heart and lung conditions is substantial, with COPD and heart failure alone accounting for over $100 billion annually in care costs in the United States. Approximately 25 million individuals in the U.S. could potentially benefit from NuvoAir's care model, indicating significant growth potential.

Competitor Analysis

NuvoAir faces competition from several key players:

Propeller Health: Focuses on respiratory health management through sensors attached to inhalers, tracking medication usage and providing insights to patients and healthcare providers.

ResMed: Offers sleep and respiratory care solutions, including CPAP devices and digital health platforms.

Philips Healthcare: Provides solutions for chronic disease management, including respiratory care devices and telehealth services.

Biogen: Develops therapies for neurological and autoimmune diseases, with research efforts extending into respiratory conditions.

Medtronic: Offers products for managing chronic diseases, including heart and lung conditions, leveraging expertise in medical devices and healthcare solutions.

Strategic Collaborations and Partnerships

NuvoAir has established several significant partnerships:

Cary Medical Management (CMM): In January 2024, NuvoAir partnered with CMM to provide in-home and virtual care for patients with complex heart and lung issues in North Carolina, enhancing access to specialty care in rural areas.